Related references
Note: Only part of the references are listed.New Developments in the Management of Cytomegalovirus Infection After Transplantation
Atibordee Meesing et al.
DRUGS (2018)
Maribavir Versus Valganciclovir for Preemptive Treatment of Cytomegalovirus (CMV) Viremia: A Randomized, Dose-Ranging, Phase 2 Study Among Hematopoietic Stem Cell Transplant (SCT) and Solid Organ Transplant (SOT) Recipients
Johan Maertens et al.
Open Forum Infectious Diseases (2017)
Burden of cytomegalovirus disease in solid organ transplant recipients: a national matched cohort study in an inpatient setting
Zalmai Hakimi et al.
TRANSPLANT INFECTIOUS DISEASE (2017)
The CYP3A biomarker 4β-hydroxycholesterol does not improve tacrolimus dose predictions early after kidney transplantation
Elisabet Storset et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
Pierre Teira et al.
BLOOD (2016)
Cytomegalovirus infection in transplant recipients
Luiz Sergio Azevedo et al.
CLINICS (2015)
The Effect of Single-and Multiple-Dose Etravirine on a Drug Cocktail of Representative Cytochrome P450 Probes and Digoxin in Healthy Subjects
Thomas N. Kakuda et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Efficacy and Safety of Maribavir Dosed at 100 mg Orally Twice Daily for the Prevention of Cytomegalovirus Disease in Liver Transplant Recipients: A Randomized, Double-Blind, Multicenter Controlled Trial
D. J. Winston et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2012)
Important Drug Interactions in Hematopoietic Stem Cell Transplantation: What Every Physician Should Know
Brett Glotzbecker et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2012)
Digoxin Is Not a Substrate for Organic Anion-Transporting Polypeptide Transporters OATP1A2, OATP1B1, OATP1B3, and OATP2B1 but Is a Substrate for a Sodium-Dependent Transporter Expressed in HEK293 Cells
Mitchell E. Taub et al.
DRUG METABOLISM AND DISPOSITION (2011)
Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial
Francisco M. Marty et al.
LANCET INFECTIOUS DISEASES (2011)
Do activities of cytochrome P450 (CYP)3A, CYP2D6 and P-glycoprotein differ between healthy volunteers and HIV-infected patients?
Alexander Jetter et al.
ANTIVIRAL THERAPY (2010)
A Randomized, Double-Blind, Pharmacokinetic Study of Oral Maribavir with Tacrolimus in Stable Renal Transplant Recipients
M. D. Pescovitz et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2009)
Viral Mimicry of Cdc2/Cyclin-Dependent Kinase 1 Mediates Disruption of Nuclear Lamina during Human Cytomegalovirus Nuclear Egress
Sofia Hamirally et al.
PLOS PATHOGENS (2009)
Effect of ketoconazole on the pharmacokinetics of maribavir in healthy adults
D. Ronald Goldwater et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study
Drew J. Winston et al.
BLOOD (2008)
Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients
C. Wyen et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the cocktail approach
U. Fuhr et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping
D. Frank et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet
W. Lawrence Drew et al.
JOURNAL OF CLINICAL VIROLOGY (2006)
Maribavir pharmacokinetics and the effects of multiple-dose maribavir on cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP 2D6, CYP 3A, N-acetyltransferase-2, and xanthine oxidase activities in healthy adults
JD Ma et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Dextromethorphan to dextrorphan urinary metabolic ratio does not reflect dextromethorphan oral clearance
S Borges et al.
DRUG METABOLISM AND DISPOSITION (2005)
Cytochrome p450 3A4 and p-glycoprotein activity and assimilation of tacrolimus in transplant patients with persistent diarrhea
W Lemahieu et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2005)
Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation
CE Staatz et al.
CLINICAL PHARMACOKINETICS (2004)
Phase I safety and pharmacokinetic trials of 1263W94, a novel oral anti-human cytomegalovirus agent, in healthy and human immunodeficiency virus-infected subjects
LH Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2003)
The human cytomegalovirus UL97 protein kinase, an antiviral drug target, is required at the stage of nuclear egress
PM Krosky et al.
JOURNAL OF VIROLOGY (2003)
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding
JP Lalezari et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action
KK Biron et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication
GW Koszalka et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Organic anion-transporting potypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver
GA Kullak-Ublick et al.
GASTROENTEROLOGY (2001)
Share Paper
